Role of
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
08 Oct 2024
08 Oct 2024
Historique:
received:
06
03
2024
accepted:
19
09
2024
revised:
12
09
2024
medline:
9
10
2024
pubmed:
9
10
2024
entrez:
8
10
2024
Statut:
aheadofprint
Résumé
The Ewing Sarcoma Family of Tumors (ESFT) constitutes a group of rare malignancies, wherein approximately one-third of cases exhibit metastatic spread, particularly impacting prognosis when bone and/or bone marrow (BM) are involved. Primary extra-pulmonary metastatic ESFT often necessitates intensified therapeutic approaches. Accurate staging plays a pivotal role in clinical decision-making, with fluorine-18-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT) currently serving as a non-invasive modality for assessing ESFT's BM extent. In the French phase II COMBINAIR3 (NCT03011528) study, a comprehensive approach for patients with extra-pulmonary ESFT metastasis was evaluated. We prospectively compared the efficacy of PET/CT to BM aspiration and biopsy (BMAB) analysis in patients undergoing initial staging. Among the 42 patients analyzed (median age 14 y, 2:1 male/female ratio), 45% presented with pelvic primary tumors and 83% had bone/BM involvement at diagnosis. Our findings showed PET/CT had 100% specificity and 83.3% sensitivity in detecting initial BM involvement. Overall, PET/CT correctly classified 92.8% of patients, reaching 100% accuracy in patients identified with bone involvement, thus surpassing the standard BMAB. These results suggest that the conventional use of BMAB in the initial staging of high-risk ESFT patients can be omitted, promoting PET/CT as a non-invasive alternative, thus improving staging accuracy and treatment decisions in ESFT management.
Sections du résumé
BACKGROUND
BACKGROUND
The Ewing Sarcoma Family of Tumors (ESFT) constitutes a group of rare malignancies, wherein approximately one-third of cases exhibit metastatic spread, particularly impacting prognosis when bone and/or bone marrow (BM) are involved. Primary extra-pulmonary metastatic ESFT often necessitates intensified therapeutic approaches. Accurate staging plays a pivotal role in clinical decision-making, with fluorine-18-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT) currently serving as a non-invasive modality for assessing ESFT's BM extent.
METHODS
METHODS
In the French phase II COMBINAIR3 (NCT03011528) study, a comprehensive approach for patients with extra-pulmonary ESFT metastasis was evaluated. We prospectively compared the efficacy of PET/CT to BM aspiration and biopsy (BMAB) analysis in patients undergoing initial staging.
RESULTS
RESULTS
Among the 42 patients analyzed (median age 14 y, 2:1 male/female ratio), 45% presented with pelvic primary tumors and 83% had bone/BM involvement at diagnosis. Our findings showed PET/CT had 100% specificity and 83.3% sensitivity in detecting initial BM involvement. Overall, PET/CT correctly classified 92.8% of patients, reaching 100% accuracy in patients identified with bone involvement, thus surpassing the standard BMAB.
DISCUSSION
CONCLUSIONS
These results suggest that the conventional use of BMAB in the initial staging of high-risk ESFT patients can be omitted, promoting PET/CT as a non-invasive alternative, thus improving staging accuracy and treatment decisions in ESFT management.
Identifiants
pubmed: 39379569
doi: 10.1038/s41416-024-02864-8
pii: 10.1038/s41416-024-02864-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Fletcher CDM, World Health Organization, International Agency for Research on Cancer, editors. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013. 468 (World Health Organization classification of tumours).
Dockhorn-Dworniczak B, Schäfer KL, Dantcheva R, Blasius S, Winkelmann W, Strehl S, et al. Diagnostic value of the molecular genetic detection of the t(11;22) translocation in Ewing’s tumours. Virchows Arch Int J Pathol. 1994;425:107–12.
doi: 10.1007/BF00230345
Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM, et al. The Ewing family of tumors–a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N. Engl J Med. 1994;331(Aug 4):294–9.
doi: 10.1056/NEJM199408043310503
pubmed: 8022439
Kovar H, Dworzak M, Strehl S, Schnell E, Ambros IM, Ambros PF, et al. Overexpression of the pseudoautosomal gene MIC2 in Ewing’s sarcoma and peripheral primitive neuroectodermal tumor. Oncogene. 1990;5(Jul):1067–70.
pubmed: 1695726
Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359:162–5.
doi: 10.1038/359162a0
pubmed: 1522903
Zoubek A, Dockhorn-Dworniczak B, Delattre O, Christiansen H, Niggli F, Gatterer-Menz I, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol J Am Soc Clin Oncol. 1996;14:1245–51.
doi: 10.1200/JCO.1996.14.4.1245
Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer. 2006;47:22–9.
doi: 10.1002/pbc.20820
pubmed: 16572419
Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, Hogendoorn PCW, et al. Impact of EWS-ETS fusion type on disease progression in Ewing’s sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol J Am Soc Clin Oncol. 2010;28:1982–8.
doi: 10.1200/JCO.2009.23.3585
Franzius C, Sciuk J, Daldrup-Link HE, Jürgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med. 2000;27:1305–11.
doi: 10.1007/s002590000301
pubmed: 11007511
Györke T, Zajic T, Lange A, Schäfer O, Moser E, Makó E, et al. Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours. Nucl Med Commun. 2006;27:17–24.
doi: 10.1097/01.mnm.0000186608.12895.69
pubmed: 16340719
Völker T, Denecke T, Steffen I, Misch D, Schönberger S, Plotkin M, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol J Am Soc Clin Oncol. 2007;25:5435–41.
doi: 10.1200/JCO.2007.12.2473
Campbell KM, Shulman DS, Grier HE, DuBois SG. Role of bone marrow biopsy for staging new patients with Ewing sarcoma: a systematic review. Pediatr Blood Cancer. 2021;68:e28807.
doi: 10.1002/pbc.28807
pubmed: 33219750
Guinot A, Tabone-Eglinger S, Isnardi V, Bahri H, Surdez D, Delattre O, et al. Staging of newly diagnosed Ewing sarcoma: Results of bone marrow aspiration and biopsy versus (18)FDG-PET/CT imaging for bone marrow involvement. Eur J Cancer Oxf Engl 1990. 2023;179:56–64.
Le Deley MC, Paulussen M, Lewis I, Brennan B, Ranft A, Whelan J, et al. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol J Am Soc Clin Oncol. 2014;32:2440–8.
doi: 10.1200/JCO.2013.54.4833
Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol J Am Soc Clin Oncol. 2012;30:4148–54.
doi: 10.1200/JCO.2011.41.5703
Ladenstein R, Pötschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol J Am Soc Clin Oncol. 2010;28:3284–91.
doi: 10.1200/JCO.2009.22.9864
Oberlin O, Rey A, Desfachelles AS, Philip T, Plantaz D, Schmitt C, et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l’Enfant. J Clin Oncol J Am Soc Clin Oncol. 2006;24:3997–4002.
doi: 10.1200/JCO.2006.05.7059
Gupta A, Riedel RF, Shah C, Borinstein SC, Isakoff MS, Chugh R, et al. Consensus recommendations in the management of Ewing sarcoma from the National Ewing Sarcoma Tumor Board. Cancer. 2023;129:3363–71.
doi: 10.1002/cncr.34942
pubmed: 37403815
Strauss SJ, Frezza AM, Abecassis N, Bajpai J, Bauer S, Biagini R, et al. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol J Eur Soc Med Oncol. 2021;32:1520–36.
doi: 10.1016/j.annonc.2021.08.1995
Haeusler J, Ranft A, Boelling T, Gosheger G, Braun-Munzinger G, Vieth V, et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer. 2010;116:443–50.
doi: 10.1002/cncr.24740
pubmed: 19924786
Karimi AM, Campbell SR, Parsai S, Angelov L, Scott J, Qi P, et al. Aggressive local control with multisite stereotactic body radiation in metastatic ewing sarcoma: a literature review and case report. Anticancer Res. 2020;40:951–5.
doi: 10.21873/anticanres.14028
pubmed: 32014939
Chan BY, Gill KG, Rebsamen SL, Nguyen JC. MR imaging of pediatric bone marrow. Radiogr Rev Publ Radio Soc N. Am Inc. 2016;36:1911–30.
Du Y, Zhao Z, Yang C. Is bone marrow biopsy and aspiration still mandatory when 18F-FDG PET/CT is available for the initial assessment of bone marrow metastasis in pediatric Ewing sarcoma? Front Oncol. 2024;14:1372481.
doi: 10.3389/fonc.2024.1372481
pubmed: 38800377
pmcid: 11116773